Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$21.57
+2.6%
$20.66
$13.40
$25.23
$3.52B0.641.98 million shs2.08 million shs
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
$10.90
+4.5%
$8.01
$3.90
$14.67
$888.89M1.54789,769 shs856,396 shs
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$31.27
+6.9%
$30.54
$21.51
$56.00
$3.53B0.911.37 million shs4.82 million shs
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
$46.99
$46.61
$28.21
$62.00
$3.54B0.682.59 million shsN/A
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
+0.67%-1.59%-4.37%+40.51%+28.80%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-2.07%+2.86%+11.91%+122.39%+22.71%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
+1.56%+2.78%-19.29%+17.94%-24.26%
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
0.00%0.00%+0.41%+26.59%+23.20%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
4.6833 of 5 stars
4.43.00.00.03.34.22.5
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
4.6214 of 5 stars
4.51.00.04.42.43.30.6
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
2.4751 of 5 stars
4.50.00.00.03.30.80.0
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
1.6508 of 5 stars
3.12.00.00.02.60.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.71
Moderate Buy$27.8829.23% Upside
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
3.00
Buy$18.5770.38% Upside
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
3.06
Buy$65.59109.75% Upside
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
2.13
Hold$52.5711.88% Upside

Current Analyst Ratings Breakdown

Latest ORIC, SWTX, RNA, and ACAD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$15.00
6/27/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$96.00
6/26/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform$19.00 ➝ $22.00
6/26/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$37.00
6/26/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
6/26/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00
6/24/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$50.00
6/23/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$26.00 ➝ $38.00
6/23/2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$20.00
6/17/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$55.00
6/11/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageStrong-Buy$65.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$957.80M3.77$0.72 per share29.82$4.40 per share4.90
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/AN/AN/AN/A$3.45 per shareN/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$10.90M345.75N/AN/A$11.94 per share2.62
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
$191.59M18.48N/AN/A$6.47 per share7.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$226.45M$1.3715.7428.384.5322.97%17.46%10.75%8/5/2025 (Estimated)
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-$127.85M-$1.870.00N/AN/AN/A-51.14%-46.29%8/11/2025 (Estimated)
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$322.30M-$3.00N/AN/AN/A-4,136.00%-26.96%-24.57%8/8/2025 (Estimated)
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
-$258.13M-$3.41N/AN/AN/A-115.60%-51.10%-43.80%8/6/2025 (Estimated)

Latest ORIC, SWTX, RNA, and ACAD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
-$0.81N/AN/AN/A$73.39 millionN/A
8/5/2025Q2 2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.14N/AN/AN/A$263.07 millionN/A
5/9/2025Q1 2025
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
-$0.81-$1.11-$0.30-$1.11$64.19 million$49.09 million
5/8/2025Q1 2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$0.88-$0.90-$0.02-$0.90$2.63 million$1.60 million
5/7/2025Q1 2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.10$0.11+$0.01$0.11$239.32 million$244.32 million
5/5/2025Q1 2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-$0.51-$0.42+$0.09-$0.42N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/AN/AN/AN/AN/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/AN/AN/AN/AN/A
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
2.88
2.80
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/A
12.00
12.00
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/A
16.91
16.91
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
N/A
4.33
4.18
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
510167.36 million123.01 millionOptionable
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
8085.22 million79.41 millionOptionable
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
190120.52 million115.90 millionOptionable
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
23075.35 million69.45 millionOptionable

Recent News About These Companies

Biotech Stocks To Consider - June 16th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$21.57 +0.55 (+2.62%)
Closing price 04:00 PM Eastern
Extended Trading
$21.58 +0.01 (+0.05%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Oric Pharmaceuticals stock logo

Oric Pharmaceuticals NASDAQ:ORIC

$10.90 +0.47 (+4.51%)
Closing price 04:00 PM Eastern
Extended Trading
$11.00 +0.10 (+0.92%)
As of 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Avidity Biosciences stock logo

Avidity Biosciences NASDAQ:RNA

$31.27 +2.02 (+6.91%)
Closing price 04:00 PM Eastern
Extended Trading
$31.50 +0.23 (+0.74%)
As of 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

SpringWorks Therapeutics stock logo

SpringWorks Therapeutics NASDAQ:SWTX

$46.99 0.00 (0.00%)
As of 07/1/2025

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.